Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Demonstrate Non-inferiority of Men-C Immune Response of Hib-MenC With Infanrix-IPV Versus a Licensed Men-C Vaccine With Pediacel When Given at 2, 3, 4 Months and the Immunogenicity of Hib-MenC When Given as a Booster Dose at 12-15 Months

Next Previous
X
Search
Trial Profile

Demonstrate Non-inferiority of Men-C Immune Response of Hib-MenC With Infanrix-IPV Versus a Licensed Men-C Vaccine With Pediacel When Given at 2, 3, 4 Months and the Immunogenicity of Hib-MenC When Given as a Booster Dose at 12-15 Months

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 27 Jun 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Hib-meningococcal vaccine group C conjugate (Primary) ; DTaP poliovirus vaccine; Hib-DTaP-poliovirus vaccine; Measles mumps and rubella virus vaccine-(Priorix); Meningococcal vaccine group C conjugate
  • Indications Diphtheria; Haemophilus infections; Meningococcal group C infections; Neisseria infections; Pertussis; Poliomyelitis; Tetanus
  • Focus Pharmacodynamics
  • Sponsors GlaxoSmithKline; GSK

    • Most Recent Events

    • 01 Nov 2008 Primary endpoint 'Antibody levels' has been met.
    • 01 Nov 2008 Primary endpoint 'Seroprotection rate' has been met.
    • 01 Nov 2008 Results published in Archives of Disease in Childhood, according to 1124825.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top